ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CLL Cello Health Plc

161.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cello Health Plc LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 161.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Cello Health PLC Board Changes (0545Y)

16/08/2018 1:30pm

UK Regulatory


Cello Health (LSE:CLL)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Cello Health Charts.

TIDMCLL

RNS Number : 0545Y

Cello Health PLC

16 August 2018

FOR IMMEDIATE RELEASE 16 August 2018

Cello Health plc

("Cello", the "Company", or the "Group")

Board Changes

Cello Health plc (AIM: CLL), the global healthcare-focused advisory Group, is pleased to announce the appointment, with immediate effect, of two independent non-executive directors to the Company's board of directors (the "Board"). The new Board members, Clifford Tompsett and Jo LeCouilliard, both have extensive experience in the pharmaceutical industry.

Clifford Tompsett was until recently a senior partner at PriceWaterhouseCoopers LLP ("PwC"), with responsibility for the firm's global cross border IPO practice. For a number of years Clifford led the firm's UK and European activities in the pharmaceutical sector, advising on many of the large deals in the industry. He was at PwC for 38 years, and is a qualified chartered accountant. Clifford will head the Board's Audit Committee and he will also be the Company's Senior Independent Director.

Jo LeCouilliard was until recently at GlaxoSmithKline plc where she held senior executive positions globally with roles in regions including the United States and Asia. Jo has also held senior hospital management positions at BMI Healthcare, and is currently a non-executive director of Circassia Pharmaceuticals plc.

In line with the plans announced at the Annual General Meeting on 10 May 2018, Paul Hamilton and Will David have both stood down as non-executive directors with immediate effect, each having served as members of the Board for more than a decade.

Mark Scott, CEO of Cello, said:

"Both Paul Hamilton and Will David have been non-executive directors of the Company since its formation. Throughout that time, they have helped the Board shape the Group into a leading international business serving predominantly health orientated clients. We are profoundly grateful for their efforts, and wish them both the best for the future.

"I am delighted that the Group has secured the services of two, highly experienced and capable new non-executive directors with deep experience across the pharmaceutical industry. The Board very much looks forward to working with Clifford and Jo as we shape the future growth path for the Group."

Regulatory information

 
 Full name (age)             Current directorships:      Previous directorships 
                                                          / partnerships (over 
                                                          the last five years): 
 Clifford Peter Tompsett     Dundas & Burgun Limited     PricewaterhouseCoopers 
  (61)                        Hatton Farm Estates         LLP 
                              Limited 
                              Kismet Acquisition 
                              Limited 
                            --------------------------  ------------------------------ 
 
 Joanna Susan LeCouilliard   Circassia Pharmaceuticals   GlaxoSmithKline Pte. 
  (54)                        plc                         Ltd. 
                                                          Glaxo Wellcome Manufacturing 
                                                          Pte. Ltd. 
                                                          General Healthcare 
                                                          Group Ltd 
                                                          Duke NUS Medical School 
                            --------------------------  ------------------------------ 
 

Mr. Tompsett and Ms. LeCouilliard do not have any interests in the ordinary shares of the Company.

There are no further disclosures to be made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of the appointments of Mr. Tompsett and Ms. LeCouilliard.

Enquiries:

 
 Cello Health plc                        020 7812 8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Group Finance Director 
 
 Cenkos Securities plc                   020 7397 8900 
 Mark Connelly 
 Harry Hargreaves 
 
 Buchanan                                020 7466 5000 
 Mark Court 
 Jamie Hooper 
 Sophie Wills 
 

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAEAAPKFAAPEFF

(END) Dow Jones Newswires

August 16, 2018 08:30 ET (12:30 GMT)

1 Year Cello Health Chart

1 Year Cello Health Chart

1 Month Cello Health Chart

1 Month Cello Health Chart

Your Recent History

Delayed Upgrade Clock